首页> 美国卫生研究院文献>other >Phase 2 Clinical Trial of High-Dose Gemcitabine/Busulfan/Melphalan for Autologous Stem-Cell Transplantation in Relapsed/Refractory Myeloma: Matched-Pair Comparison with Melphalan

【2h】

Phase 2 Clinical Trial of High-Dose Gemcitabine/Busulfan/Melphalan for Autologous Stem-Cell Transplantation in Relapsed/Refractory Myeloma: Matched-Pair Comparison with Melphalan

机译：大剂量吉西他滨/环丁砜/美法仑用于复发/难治性骨髓瘤自体干细胞移植的2期临床试验：与美法仑的配对配对比较

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

AI期刊论文写作 >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

BACKGROUNDHigh-dose melphalan is of limited benefit as autologous stem-cell transplantation (ASCT) regimen for relapsed/refractory myeloma. Its poor results in this setting prompted us to study a new high-dose combination of infusional gemcitabine/busulfan/melphalan (Gem/Bu/Mel).

机译：背景大剂量美法仑作为复发/难治性骨髓瘤的自体干细胞移植（ASCT）方案的益处有限。在这种情况下其不良的结果促使我们研究了吉西他滨/白消安/美法仑（Gem / Bu / Mel）输注的新型大剂量组合。

著录项

期刊名称 other
作者
Yago Nieto; Benigno C Valdez; Sai R Pingali; Roland Bassett; Ruby Delgado; John Nguyen; Nina Shah; Uday Popat; Roy B Jones; Borje S Andersson; Alison Gulbis; Sairah Ahmed; Qaiser Bashir; Simrit Parmar; Krina Patel; Alan Myers; Gabriela Rondon; Robert Z Orlowski; Richard Champlin; Muzaffar Qazilbash;
展开▼
作者单位

展开▼
年(卷),期 -1(4),6
年度 -1
页码 e283–e292
总页数 18
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma [J] . Yago Nieto, Peter F. Thall, Junsheng Ma, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2018,第8期

机译：None
2. High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid Malignancies [J] . NietoY., ThallP., ValdezB., Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2012,第11期

机译：大剂量吉西他滨联合白消安和美法仑联合自体干细胞移植治疗难治性淋巴恶性肿瘤
3. Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma [J] . Luciano J. Costa, Heather J. Landau, Saurabh Chhabra, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2018,第7期

机译：Carfilzomib的第1/2阶段试验加上高剂量Melphalan制备方案，用于拯救自体造血细胞移植，然后在复发/难治性多发性骨髓瘤患者中进行维持尸体喹啉
4. HIGH-DOSE MELPHALAN CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN 65 PATIENTS WITH AL AMYLOIDOSIS: ORGAN PROGRESSION CAN BE DELAYED IN PATIENTS REACHING COMPLETE REMISSION [C] . SO Schonland, J.B Dengler, M Hundemer, International Symposium on Amyloidosis . 2008

机译：在65例Al淀粉样蛋白患者中，具有自体蛋白化疗的高剂量蛋白化疗：器官进展可以延迟达到完全缓解的患者
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplant in Patients with Refractory Lymphoid Malignancies [O] . Y Nieto, P Thall, B Valdez, -1

机译：高剂量注入吉西他滨联合Busulfan和Melphalan与难治性淋巴恶性肿瘤患者的自体干细胞移植
7. Comparison of Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) with Beam and Busulfan/Melphalan (Bu/Mel) in Concurrent Cohorts of Refractory Hodgkin'S Lymphoma (HL) Patients Receiving an Autologous Stem-Cell Transplant [O] . Nieto Y., Jones R.B., Liu P., 2012

机译：吉西他滨，白消安和美法仑（Gem / Bu / Mel）与束和白消安/美法仑（Bu / Mel）在难治性霍奇金淋巴瘤（HL）并发自体干细胞移植患者中的比较

Phase 2 Clinical Trial of High-Dose Gemcitabine/Busulfan/Melphalan for Autologous Stem-Cell Transplantation in Relapsed/Refractory Myeloma: Matched-Pair Comparison with Melphalan

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅